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Abstract
HIV mutates rapidly and infects CD4+ T cells, especially when they are activated. A vaccine
targeting conserved, essential viral elements while limiting CD4+ T cell activation could be
effective. Learning from natural immunity observed in a group of highly HIV-1 exposed sero-
negative Kenyan female sex workers, we are testing a novel candidate HIV vaccine target-
ing the 12 viral protease cleavage sites (PCSs) (the PCS vaccine), in comparison with a
vaccine targeting full-length Gag and Env (the Gag/Env vaccine) in a Mauritian cynomolgus
macaque/SIV model. In this study we evaluated these vaccines for induction of mucosal
antibodies to SIV immunogens at the female genital tract. Bio-Plex and Western blot analy-
ses of cervicovaginal lavage samples showed that both the PCS and Gag/Env vaccines can
elicit mucosal IgG antibody responses to SIV immunogens. Significantly higher increase of
anti-PCS antibodies was induced by the PCS vaccine than by the Gag/Env vaccine
(p<0.0001). The effect of the mucosal antibody responses in protection from repeated low
dose pathogenic SIVmac251 challenges is being evaluated.
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Introduction
Development of an effective vaccine to human immunodeficiency virus type 1 (HIV) has
proven to be a daunting task. Of the six HIV vaccine trials, the RV144 trial was the only one
that demonstrated a modest efficacy (31.2%) [1, 2]. HIV primarily targets activated CD4+ T
cells—a major arm of the immune system [1], apart from its capacity to mutate to evade
immune recognition and generate extensive sequence variability [3–5]. Thus, a HIV vaccine
generating immune response to conserved, functionally essential viral elements [6], and in the
meantime limiting the generation of viral target cells [7, 8], could be more effective [1, 9–18].
The HIV protease cleaves Gag, Gag-Pol and Nef precursor proteins at twelve protease cleav-
age sites (PCSs) during viral maturation [18, 19]. The process is highly specific, temporally reg-
ulated and essential for generating infectious viral particles [20–25]. Even subtle disturbance
can be sufficient to interrupt this delicately balanced process and drive it toward a non-pro-
ductive end [20, 23, 24, 26]. Consistent with their critical function, the sequences surrounding
the PCSs are highly conserved among major HIV subtypes [27]. Drugs targeting Gag that
impair protease-mediated processing at specific Gag cleavage sites have been developed [28].
A HIV vaccine targeting the viral protease cleavage sites (PCSs) has been proposed for its abil-
ity to generate antiviral immune responses, disrupt HIV maturation and limit target cell acti-
vation [10, 18, 27].
Simian immunodeficiency virus (SIV) infection of nonhuman primates (NHPs) is currently
the best animal model to test HIV vaccine strategies or study HIV pathogenesis [29–42]. To
evaluate a candidate HIV vaccine targeting the PCSs (PCS vaccine), we use female Mauritian
cynomolgus macaques (MCMs) and SIVmac as a model. The PCS vaccine [35] consists of
twelve 20-mer peptides overlapping the twelve PCSs of SIVmac239 [43–45]. These peptides
were delivered with recombinant vesicular stomatitis virus (rVSV) [46] and nanoparticles
(NANO) [47–51]. In parallel, we also evaluate a vaccine targeting full-length Gag and Env
(Gag/Env vaccine).
The majority of HIV infections worldwide are acquired through the mucosal routes during
sexual contact [52]. Women are especially vulnerable through vaginal exposure to HIV in sem-
inal fluids and constitute more than half of all infections globally [53]. Therefore, inducing a
protective immune response at mucosal sites, including the female genital tract, is extremely
important in HIV vaccine development [53–56]. In this study, we evaluated the PCS vaccine
in comparison with the Gag/Env vaccine in generating mucosal antibody responses to differ-
ent immunogens, which may impact on the outcome of viral challenge [57].
Materials and methods
Ethics statement
Female Mauritian cynomolgus macaques (MCMs) were pair-housed within the same experi-
mental group during the immunization phase of the study with visual and auditory access to
other conspecifics. Paired monkeys lived in two adjacent standard stainless-steel primate cages
(27”L x 27”W x 32”H per cage). Rooms were maintained at 65–75˚F, 30–70% humidity, and
on a 12:12 light-dark cycle (ON: 0600, OFF: 1800). Standard nonhuman primate chow with
fruit or vegetables was provided daily. In addition, we provided foraging activities and physical
environmental enrichment at least weekly for both activities. All animals were observed at
least twice daily for health or welfare issues. Sedation (ketamine alone, or ketamine/dexmede-
tomidine, atipamezole for reversal) was provided during the experimental procedures. The
experiments were approved by the University of Wisconsin IACUC protocol (G005765) in
accordance with the US Animal Welfare Act and following the recommendations of the
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Production of high titer rVSVpcs
The sequence of Simian immunodeficiency virus strain SIVmac239 was retrieved from the Los
Alamos National Laboratory HIV database (http://www.hiv.lanl.gov). The nucleotide sequence
encoding 20 amino acids (10 amino acids flanking each side of the cleavage site) overlapping
each of the 12 PCSs of SIVmac239 was previously cloned in a recombinant vesicular stomatitis
virus (rVSV) vector, pATX VSV-G, and packaged into rVSVpcs virus [35]. To generate large
viral stocks for macaque immunization, VeroE6 cells were grown to 90% confluence in a T175
flask with 25 ml media, Dulbecco’s modified Eagle’s medium (DMEM) containing 10% fetal
bovine serum (FBS), penicillin (100 U/ml), streptomycin (100 μg/ml) and L glutamine (2mM)
(Invitrogen, CA, USA). 20 ml of the old culture media was removed and replaced with the
same volume of fresh media 30 min before viral inoculation. Approximately 1×106 plaque
forming units (pfu) of rVSVpcs virus was then added to the cell culture and allowed to prolif-
erate for 12–24 hours until 90–100% cell death was observed. The culture supernatants were
harvested and centrifuged at 180 g/min for 5 min at room temperature to remove cellular
debris.
To concentrate and purify rVSVpcs using density gradient ultracentrifugation, 20 ml of the
supernatants were gently layered on top of 8 ml of equilibration buffer (20 mM Tris-HCl, 0.1
M NaCl and 0.1 mM EDTA) containing 20% sucrose (Fisher Scientific) in an Ultra-Clear™
centrifugation tube (Beckman Coulter). To make the equilibration buffer, 20 ml of Ultra Pure
1M Tris-HCl pH7.5 (Invitrogen), 20 ml of 5M NaCl (Invitrogen) and 200 μl of 0.5M EDTA
pH8.0 (Ambion) were diluted with sterile water to 1L. Sucrose was freshly added to the equili-
bration buffer on the day of viral purification. Ultracentrifugation was performed in a Beck-
man Coulter XPN-80 Ultracentrifuge using the SW 32 Ti rotor at 27,000 rpm for 2h at 4˚C.
After carefully removing the supernatants, viral pellets were resuspended in 1 ml DMEM con-
taining 10% FBS, and finally stored as 100 μl aliquots in a -80˚C freezer.
Viral titers were calculated using the TCID50 calculator by Marco Binder (https://www.
researchgate.net/file.PostFileLoader.html?id=58dad730f7b67ea37125593f&assetKey=AS%
3A476999471898624%401490736944531), based on cytopathic effect of serially diluted viral
stocks on VeroE6 cells.
Packaging of PCS peptides into nanoparticles (NANOpcs)
Twelve synthetic 20mer peptides overlapping the PCSs of SIVmac239 were associated to a bio-
degradable nanoparticle system formed by chitosan and dextran sulfate, as previously
described [35].
Generation of rVSVGag/Env vaccine
Full-length Gag and Env coding sequences of SIVmac239 were synthesized and cloned in a
Blue Heron pUC(-)MCS plasmid (BlueHeron Biotechnology, Bothell, WA, USA). Each gene
sequence was flanked by an upstream MluI restriction site (AAACGCGT), Kozak sequence
(GCCACC), start codon, and downstream stop codon and AvrII restriction site (CCTAGGTT).
Using these restriction sites, the Gag and Env coding fragments were each sub-cloned into the
rVSV vector pATX VSV-G, followed by confirmation with sequencing, and packaged into
rVSVgag/env viruses, based on the previously described methods for rVSVpcs [35]. Large
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stocks of high-titer purified rVSVgag/env viruses were produced with the same methods as
described above for rVSVpcs. As a control vaccine vector, wild type virus (rVSV) was similarly
produced. To test SIV protein expression, supernatants from VeroE6 cell cultures infected
with these rVSVs were analyzed by Western blot.
Generation of NANOgag/env DNA vaccine
Using the above-mentioned Blue Heron pUC(-)MCS-Gag/Env plasmids as templates, full-
length Gag and Env genes were PCR amplified with primers introducing an EcoRI restriction
site upstream of the Kozak sequence and start codon and an XhoI restriction site downstream
of the stop codon. These primers were:
Forward Gag primer: 5’CCGGAATTCGCCACCATGGGCGTGAGAAACTCCG3’
Reverse Gag primer: 5’CCGCTCGAGCTACTGGTCTCCTCCAAAGAGAG3’
Forward Env primer: 5’CCGGAATTCGCCACCATGGGATGTCTTGGGAATC-3’
Reverse Env primer: 5’CCGCTCGAGTCACAAGAGAGTGAGCTCAAGC-3’
The PCR products were then sub-cloned into a DNA vaccine vector, pVAX1, between the
EcoRI and XhoI sites, followed by confirmation with sequencing.
The resulting full-length Gag and Env-coding DNA constructs, pVAX1-Gag and pVAX1-Env,
were each packaged into DNA vaccine nanoparticles (NANOgag and NANOenv, also collectively
named NANOgag/env when administered together), according to the ionotropic gelation tech-
nique previously published [58]. Chitosan (Heppe Medical Chitosan GmbH, Halle, Germany)
and tripolyphosphate (TPP, Sigma-Aldrich, St. Louis, MO, USA) were separately dissolved in
ultrapure water at a concentration of 0.625 mg/mL and 2 mg/mL, respectively. Then 0.7 mL of
TPP at the concentration of 2 mg/mL was mixed with 2.1 mL of 0.33 mg/mL solution of plasmid.
This mixture was slowly added over 11.2 mL of chitosan solution at a concentration of 0.625 mg/
mL, under magnetic stirring. Nanoparticles were instantly formed upon the addition, and the
mixture was kept under stirring for 10 minutes. For the freeze-drying process, 0.65 mL of a fil-
tered solution of trehalose at 150 mg/mL was added to 6.5 mL of the nanoparticle suspension.
Samples were frozen at -80˚C and subsequently freeze-dried (Genesis 25 ES, VirTis Model-Wiz-
ard 2.0, SP Industries, USA). Prior to animal administration, the freeze-dried particles were resus-
pended by adding 0.65 mL of water, vortexing for 10 seconds and shaking horizontally for 10
minutes. The physical characteristics of the freeze-dried particles after resuspension included:
size (NANOgag = 235 ± 4 nm and NANOenv = 225 ± 18 nm), polydispersity index (both 0.2)
and zeta potential (NANOgag = +38 ± 3 mV and NANOenv = +39 ± 4 mV).
To test SIV protein expression, the Gag and Env DNA vaccine constructs were each used to
transfect HEK293T cells using lipofectamine 2000 (Thermo Fisher Scientific, Waltham, MA,
USA). HEK293 T cells were cultured to 90% confluence (in the same media as used for
VeroE6 described above) in 6-well plates. Before transfection, the media were replaced with 2
ml of antibiotic-free DMEM containing 10% FBS. 2.5 μg DNA and 10 μl lipofectamine 2000
were diluted separately in 250 μl Opti-MEM (Thermo Fisher Scientific). The diluted DNA was
mixed with the diluted lipofectamine 2000 and incubated for 5 min at room temperature. The
DNA-lipid complex was then added to the cells. Transfected cells were harvested 24 h post
transfection. Approximately 1×106 cells were lysed with 50 μl RIPA lysis and extraction buffer
(Thermo Fisher Scientific), then passed through a QIAshredder column (Qiagen) by centrifu-
gation at 15,000 g for 2 min. The processed lysates were finally analyzed by Western blot.
Vaccination
Three groups of eight female MCMs were used in the study. Group 1, the PCS vaccine group
received rVSVpcs (viruses expressing PCS peptides) and NANOpcs (nanoparticles containing
Mucosal antibodies to SIV vaccines
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PCS peptides), Group 2, the Gag/Env vaccine group received rVSVgag/env (viruses expressing
full-length Gag and Env proteins) and NANOgag/env (nanoparticles containing plasmid DNA
encoding full-length Gag and Env), and Group 3, the Control group received vaccine vector
controls (empty rVSV virus, and sterile water—the nanoparticle vehicle). One animal from the
Gag/Env vaccine group was euthanized early due to severe health issues unrelated to vaccina-
tion, leaving seven animals in this group to complete the study. The vaccination procedure
consisted of a prime with rVSVs at week 0, the first boost with rVSVs + NANOs at week 6, the
second boost with NANOs at week 16, the third boost with rVSVs + NANOs at week 51 and
the fourth boost with rVSVs at week 72, respectively. All rVSVs were administered intramus-
cularly via the quadriceps muscle, alternating L and R for successive vaccinations. The dose
was at 1×106 pfu of each rVSVpcs per animal of the PCS Vaccine group or 6×106 pfu of
rVSVgag and 6×106 pfu of rVSVenv per animal of the Gag/Env Vaccine group, except that for
the 4th boost 1×108 pfu/rVSV type/animal were administered. All NANOs were administered
intranasally, with each animal receiving NANO-delivered 50 μg peptide for each of the twelve
PCS peptides (the PCS vaccine group) or NANO-delivered plasmid DNA encoding Gag
(500 μg) and Env(500 μg) (the Gag/Env vaccine group).
Cervicovaginal lavage (CVL) sample collection
The vaginal lumen of sedated animals was rinsed with 2–6 ml of phosphate buffered saline
(PBS) non-traumatically using a needleless syringe. Within this volume range, the total
amount of PBS used varied from animal to animal because of the varying sizes of their cervical
vaults. The PBS was administered until the vault is full and then collected back into the same
syringe. The fluid was gently flushed five times using the same syringe and repeated until 2–4
ml of fluid was collected. To take the volume variation into account, mucosal antibody concen-
trations were all normalized to total protein concentrations of the collected samples. The CVL
sample collection was performed non-traumatically with extreme caution to avoid blood con-
tamination from tissue damage. In addition, the animals were examined every day for menses
and we have kept a daily menses record during the study. Due to variable dates of menstrua-
tion among individual female macaques and fixed dates of sampling schedule, it was practically
difficult to avoid menstruation dates in all CVL collections. Indeed a small percentage of sam-
ples (11.25%) were collected on menstruation dates. To rule out effect of any potential menses
blood contamination, we excluded data of the samples collected during menstruation from
final analysis. All CVL sample aliquots were stored at -80˚C until use.
Bio-Plex antibody assay
CVL IgG antibodies to SIV antigens were quantified by following a previously published Bio-
Plex multiplexed protocol [35]. CVL total protein concentrations were determined using a
NanoOrange1 protein quantitation kit (Thermo Fisher Scientific) according to the manufac-
turer’s protocol. The IgG antibody level was normalized with the total protein concentration.
Western blot
Western blot was used to detect: (1) SIV Gag and Env protein antigens expressed from rVSV
and DNA Gag/Env vaccines; and (2) Vaccination-induced antibodies to purified recombinant
Gag and Env proteins (NIH AIDS reagent program). Western blot was conducted following a
previously published method [35] with slight modifications. For detection of antigens, 26 μl of
supernatants from rVSV-infected VeroE6 cell culture, or lysates of DNA vaccine-transfected
HEK293T cells equivalent to 5×105 cells, were diluted and denatured in the format of a 40 μl
NuPAGE sample and loaded for SDS-PAGE, followed by blotting. Gag and Env protein
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antigens were probed with standard mouse monoclonal antibodies (NIH AIDS Reagent Pro-
gram) as listed in the published method [35]. For detection of antibodies, 1 μg of purified
recombinant SIV proteins (NIH AIDS Reagent Program), SIVmac251 Gag (Catalog 1845) and
SIVmac239 Env (Catalog 12797), were used as standard antigens for blotting. CVL samples
from the control, PCS vaccine and Gag/Env vaccine groups of animals were 1:10 diluted and
used as primary antibodies. IgG antibodies bound to the antigens were then detected using an
anti-monkey IgG-HRP secondary antibody [35].
Statistical analysis
Mann Whitney’s test was conducted using GraphPad Prism 7.04 to compare antibody
responses among the PCS vaccine, Gag/Env vaccine and control groups. A p value less than
0.05 was defined as significant.
Results
Generation of the PCS vaccine and the Gag/Env vaccine
The PCS vaccine consists of twelve 20-amino acid peptides each overlapping one of the twelve
PCSs of SIVmac239 (PCS1 through PCS12) (Fig 1A and 1B). The PCS immunogens were
delivered in recombinant vesicular stomatitis virus (rVSVpcs) and nanoparticles (NANOpcs).
rVSV is a non-pathogenic, replication competent viral vector. It can induce robust humoral
and cellular immune responses, and unlike adenoviral vectors, lacks pre-existing human
immunity [46]. The success of the vector was demonstrated by the safety and protective effi-
cacy of an Ebola virus vaccine [59, 60]. Biodegradable NANO materials have great capacity for
mucosal vaccination [47, 48, 50, 51, 61] as demonstrated by its successful nasal delivery of teta-
nus toxoid [61, 62] and hepatitis B surface antigen [47, 49, 63] subunit vaccines. For simplicity,
the rVSVpcs and NANOpcs were collectively referred to as the PCS vaccine, as both were used
in combination to immunize the same group of animals. The PCS vaccine was shown to
induce plasma antibodies to the PCS peptides in a pilot study [35]. For comparison, we gener-
ated a rVSV vaccine with full-length Gag and Env genes of SIVmac239 (rVSVgag/env). The
expression of Gag and Env proteins by rVSVgag/env was confirmed by Western blot using
VeroE6 cell cultures infected by these viruses (Fig 1D). Gag and Env-expressing DNA vaccines
in pVAX1 were also generated to be delivered with nanomaterial for boosting immune
response to Gag and Env (NANOgag/env). The expression of Gag and Env proteins from the
DNA vaccine constructs was confirmed by Western blot in transfected HEK293T cells (Fig
1D). The rVSVgag/env and NANOgag/env in combination were named the Gag/Env vaccine,
to be compared with the PCS vaccine.
The immunization scheme
We carefully considered the routes of vaccination as they are well known factors to impact on
the localized induction of immune responses. In general, systemic delivery of immunogens
tends to elicit systemic responses and mucosal delivery of immunogens tends to induce muco-
sal immune responses [53]. However, systemically delivered viral vectors can also induce
mucosal immune responses to HIV or SIV [64, 65]. Mucosal vaccination at one site stimulates
immune responses in all mucosal sites, as well as systemic immune responses [53]. Intranasal
immunization was reported to be the most effective at eliciting immune responses in the
female genital tract [66], and this route induces greater IgG systemic responses than other
mucosal routes, oral, rectal or vaginal [67]. It was proposed that systemic prime followed by
mucosal boosting may help prevent induction of mucosal tolerance by initial mucosal
Mucosal antibodies to SIV vaccines
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vaccination, and should elicit both systemic and mucosal antibodies [53]. Taking all these into
considerations, we chose to use rVSVs for systemic prime and boost through the intramuscu-
lar route (i.m.) and NANOs for mucosal boost through the intranasal route (i.n.). The resulting
vaccination scheme consisted of a prime with rVSVs and four boosts with combinations of
rVSVs and NANOs, as illustrated in Fig 1E.
Mucosal SIV-specific IgG antibodies elicited by vaccine modalities
targeting different immunogens of SIVmac239
Protective mucosal immune responses to HIV is critical in preventing its mucosal transmis-
sion [52, 53]. In several passive and active NHP immunization experiments mucosal IgG anti-
bodies showed protective effect against simian-human immunodeficiency virus (SHIV)
acquisition (57–65). Therefore, we analyzed mucosal antigen-specific IgG responses after
MCMs were primed and boosted with the PCS vaccine or the Gag/Env vaccine following the
vaccination scheme illustrated in Fig 1E. Cervicovaginal lavage (CVL) samples were collected
and measured for IgG responses to the twelve PCS peptides and three Gag/Env (non-PCS)
peptides, SIVgag, SIVenv1 and SIVenv2 (Fig 1C) by Bio-Plex and to Gag and Env proteins by
Western blot.
We first analyzed the dynamics of antibodies to each of the twelve PCS peptides (PCS1 –
PCS12) throughout the vaccination procedure. These antibodies showed trend of increase in
the PCS vaccine group compared to the Gag/Env vaccine and Control group after prime, the
1st boost and the 4th boost (Fig 2). Similar patterns were observed in the dynamics of antibod-
ies to non-PCS Gag/Env peptides (SIVgag, SIVenv1 and SIVenv2) (Fig 3). We also observed
variable antibody responses to PCS peptides among individual animals in the PCS vaccine
(Figure A in S1 File), Gag/Env vaccine (Figure B in S1 File) and Control (Figure C in S1
File) groups, by comparing antibody levels between the baseline and one week after the last
boost (4th). Six out of seven animals (85.7%) from the PCS vaccine group (Figure A in S1
File) and three out of six animals (50%) from the Gag/Env vaccine group (Figure B in S1 File)
showed consistent increase in IgG antibodies to all PCS peptides. In contrast, only one out of
eight animals (12.5%) from the control group showed a similar pattern (Figure C in S1 File).
Similar results were also seen in antibody responses to Gag/Env peptides (Figures D-F in S1
File).
We quantified the effect of prime, each boost and the full vaccination process on antibody
responses to each PCS. The PCS vaccine group showed trends of higher fold increase of
Fig 1. Vaccines targeting SIV protease cleavage sites (PCSs) or full Gag and Env proteins. (A) Diagram of the twelve protease cleavage sites (PCS1 through
PCS12), located on three SIV polyproteins (Pr55Gag, Pr160Gag-Pol and Nef precursor), not drawn to scale. MA: matrix; CA: capsid; NC: nucleocapsid; TFP:
transframe protein; PR: protease; RT: reverse transcriptase; and IN: integrase. (B) Peptide sequences of SIV immunogens in a conserved element vaccine
targeting the PCSs (the PCS vaccine). Each sequence corresponds to -10 through +10 amino acid positions flanking each cleavage site. Slash (/) indicates the
site of protease cleavage. These sequences were confirmed to be specific for SIV by NCBI protein BLAST and conserved among multiple SIV strains. The
peptide immunogens were delivered as recombinant vesicular stomatitis viruses (rVSVpcs) and nanoparticles (NANOpcs). Peptide antigens with these
sequences were also used in a Bio-Plex multiplexed assay to detect anti-PCS antibodies. (C) Sequences of three Gag or Env (non-PCS) peptides used in Bio-
Plex to detect anti-Gag or Env antibodies, including one Gag peptide, named SIVgag, and two Env peptides, named SIVenv1 and SIVenv2. (D) Western blot
analyses of protein expression from a full-length Gag and Env-based vaccine (the Gag/Env vaccine). VeroE6 cells were infected with recombinant vesicular
stomatitis viruses (rVSVs) carrying full Gag or Env gene of SIVmac239 (rVSVgag/env) and the culture supernatants were analyzed by Western blot to detect
Gag or Env protein expression using standard monoclonal antibodies (mAb, NIH AIDS Reagent Program) to Gag or Env. The full Gag and Env genes were
also cloned into pVAX1 (a DNA vaccine vector), respectively, followed by NANO packaging (NANOgag/env). HEK293T cells were transfected with these
DNA vaccines and analyzed by Western blot. (E) Vaccination scheme. Three groups (Control, PCS vaccine and Gag/Env vaccine) of eight female MCMs per
group were primed and boosted on indicated weeks (wk). The Control group received empty rVSV virus and sterile water. One animal from the Gag/Env
vaccine group was euthanized early due to severe health issues unrelated to vaccination, leaving seven animals in this group to complete the study. rVSV
control vector (rVSV), rVSVpcs or rVSVgag/env was administered intramuscularly. NANO control vector (sterile water), NANOpcs or NANOgag/env was
administered intranasally.
https://doi.org/10.1371/journal.pone.0202997.g001
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antibodies (after prime, the 1st boost, the 4th boost, or the full vaccination process) than the
other groups (Fig 4).
We then calculated the effect of vaccines on total antibody responses to all PCSs by includ-
ing antibodies to all PCS sites collectively as anti-PCS antibodies since they all target the viral
Fig 2. Dynamics of PCS-specific IgG antibodies in cervicovaginal secretions. Cervicovaginal lavage (CVL) samples from the vaccination experiments
illustrated in Fig 1E were quantified for levels of IgG antibodies to each PCS peptide (y axis, expressed as ratios of anti-PCS IgG concentration to total
protein concentration ×109) by a Bio-Plex multiplexed antibody assay, at indicated time points (x axis, weeks post prime). The Control group received
empty rVSV virus and sterile water. Data are shown as each value from individual animals with median line, following subtraction of pre-vaccination
values. Total animal numbers per group examined are n = 8 (Control or PCS group) or n = 7 (Gag/Env group). However, for technical stringency,
animal samples collected on menstruation dates were excluded from analysis to rule out any potential menses blood contamination. As a result, for some
of the data points in the graph, fewer individual values than the total animal number (n = 8 or n = 7) were available. Grey areas indicate a week interval
post prime, 1st boost or 4th boost, with trends of antibody increase in the PCS vaccine group in response to vaccination. The trends did not reach
statistical significance.
https://doi.org/10.1371/journal.pone.0202997.g002
Fig 3. Dynamics of Gag/Env-specific IgG antibodies in cervicovaginal secretions. Cervicovaginal lavage (CVL)
samples from the vaccination experiments illustrated in Fig 1E were quantified for IgG antibodies to Gag/Env (non-
PCS) peptides, SIVgag, SIVenv1 and SIVenv2 (y axis, expressed as ratios of anti-non-PCS IgG concentration to total
protein concentration ×109) by a Bio-Plex multiplexed antibody assay, at indicated time points (x axis, weeks post
prime). The Control group received empty rVSV virus and sterile water. Data are shown as each value from individual
animals with median line, following subtraction of pre-vaccination values. Total animal numbers per group examined
are n = 8 (Control or PCS group) or n = 7 (Gag/Env group). However, for technical stringency, animal samples
collected on menstruation dates were excluded from analysis to rule out any potential menses blood contamination. As
a result, for some of the data points in the graph, fewer individual values than the total animal number (n = 8 or n = 7)
were available. Grey areas indicate a week interval post prime, 1st boost or 4th boost, with trends of antibody increase in
the PCS vaccine group in response to vaccination. The trends did not reach statistical significance.
https://doi.org/10.1371/journal.pone.0202997.g003
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Fig 4. Fold changes of mucosal antibodies to each PCS peptide in response to vaccinations. Graphs show fold changes of mucosal IgG antibodies to each
PCS peptide (1 through 12) between the time of a prime/boost and one week after that single prime/boost (Prime, 1st, 2nd, 3rd or 4th), or between the baseline
(the start of the full vaccination procedure) and one week after the last boost (the end of the full vaccination procedure) (Full). The Control group received
empty rVSV virus and sterile water. Data are shown as each value from individual animals with interquartile range and median line. Total animal numbers per
group examined are n = 8 (Control or PCS group) or n = 7 (Gag/Env group). However, for technical stringency, animal samples collected on menstruation
dates were excluded from analysis to rule out any potential menses blood contamination. As a result, for some of the data points in the graph, fewer individual
values than the total animal number (n = 8 or n = 7) were available. Fold changes of antibodies in response to prime, the 1st boost, the 4th boost and the full
vaccination procedure showed trends of increase in the PCS vaccine group, compared to the other groups. The trends did not reach statistical significance.
https://doi.org/10.1371/journal.pone.0202997.g004
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protease cleavage function. The fold changes of total anti-PCS antibodies, in response to
prime, the 1st boost, the 4th boost or the full vaccination process, were significantly higher in
the PCS vaccine group than those in the Gag/Env vaccine group and the Control group
(p< 0.0001) (Fig 5). Among these, the mean fold changes induced by the 4th boost were
12.353 (PCS vaccine), 3.465 (Gag/Env vaccine) and 1.792 (Control), and those induced by the
full vaccination process were 25.466 (PCS vaccine), 3.005 (Gag/Env vaccine) and 1.853 (Con-
trol) (Fig 5). These results indicated that the PCS vaccine can effectively induce mucosal anti-
PCS antibodies at the female genital tract and has a stronger effect than the Gag/Env vaccine.
We also examined the effect of vaccines on antibody responses to Gag/Env. The PCS vac-
cine group showed trends of higher fold increase in antibodies to two non-PCS Gag/Env pep-
tides, SIVgag and SIVenv1, after prime, the 1st boost, the 4th boost, and the full vaccination
process, in comparison to the Control group (Fig 6A). The fold increase of antibodies to the
three non-PCS Gag/Env peptides was not apparent in the Gag/Env group or the Control
group (Fig 6A). We then tested antibody reactivity by Western blot using Gag and Env pro-
teins, which were expected to detect antibodies that recognize epitopes not limited to the three
Gag/Env peptides. Antibodies of vaccinated animals from the PCS and Gag/Env vaccine
groups recognized purified recombinant Gag protein (rGag) (Fig 6B). While antibodies from
the Gag/Env group showed strong reactivity to purified recombinant Env protein (rEnv),
those from the PCS vaccine group demonstrated weak but clear reactivity to rEnv (Fig 6B).
These results indicated that the PCS and Gag/Env vaccines can induce mucosal IgG antibodies
to Gag and Env.
Cross-reactivity of the vaccine-induced antibodies
Bio-Plex antibody assays suggested that the PCS vaccine, which delivers PCS peptides, induced
antibodies that recognize non-PCS Gag/Env peptides (Figs 3 and 6A). The antibody cross-
reactivity was supported by Western blot analyses demonstrating that these antibodies reacted
Fig 5. Fold changes of collective anti-PCS antibodies in response to vaccinations. Mucosal IgG antibodies to all individual PCS types (PCS1 through
PCS12) were collectively treated as anti-PCS antibodies for calculation. Graph shows fold changes between the time of a prime/boost and one week after
that single prime/boost (Prime, 1st, 2nd, 3rd or 4th), or between the baseline (the start of the full vaccination procedure) and one week after the last boost
(the end of the full vaccination procedure) (Full). The Control group received empty rVSV virus and sterile water. Total animal numbers per group
examined are n = 8 (Control or PCS group) or n = 7 (Gag/Env group). However, for technical stringency, animal samples collected on menstruation
dates were excluded from analysis to rule out any potential menses blood contamination. Bars represent mean ± SEM. The PCS vaccine group
demonstrated significantly higher fold induction of anti-PCS antibodies than the Gag/Env vaccine and Control groups, in response to prime, the 1st
boost, the 4th boost and the full vaccination procedure, as determined by Mann Whitney’s test:  p< 0.0001.
https://doi.org/10.1371/journal.pone.0202997.g005
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to rGag and rEnv proteins (Fig 6B). The rGag protein contains peptide sequences of PCSs
(PCS1 through PCS5) (Fig 1), thus it was expected that the antibodies induced by the PCS vac-
cine could recognize Gag. However, rEnv does not contain any PCS sequence (Fig 1), there-
fore the induction of anti-Env antibodies by the PCS vaccine was unexpected. While the
underlying mechanism(s) of the cross-reactivity remain to be understood, these data indicated
that the PCS vaccine can generate antibodies to both PCS peptides and Env.
Discussion
In this study we examined mucosal antibodies induced by two different modalities of candi-
date HIV/SIV vaccines, a vaccine targeting short peptide sequences overlapping the 12 prote-
ase cleavage sites and a vaccine targeting full Gag and Env of SIVmac239. Since 90% of HIV
transmissions occur through the mucosal route [68] and male to female sexual transmissions
account for more than half of all HIV infections [53], it is important to test whether a candi-
date vaccine can induce mucosal immune responses to HIV/SIV antigens. Our study showed
that both the PCS vaccine and Gag/Env vaccine can induce cervicovaginal mucosal IgG anti-
bodies to SIV antigens, including PCSs, Gag and Env. The PCS vaccine preferentially gener-
ated mucosal IgG antibodies to the PCS peptides, whereas the Gag/Env vaccine generated
much stronger mucosal IgG antibodies to Env.
Most of current vaccine studies on anti-HIV antibodies are focused on Env-specific anti-
bodies. However, it was also shown that antibodies to Gag and Pol correlated with natural and
post vaccination HIV control [69–74], suggesting that antibodies targeting Gag and Pol could
be protective. Not only Env, but also Gag and Pol were included in the vaccine used for the
RV144 trial, the only vaccine so far with efficacy against HIV acquisition [2]. A previous pre-
clinical study also showed that Gag was required for protection against SIVsmE660 challenge
[75]. Potential protective effect of the mucosal antibodies to PCSs, Gag and Env induced by
different modalities of vaccines in the current study will be evaluated in repeated low dose SIV-
mac251 intravaginal challenges.
We observed that without SIV-specific immunization, antibodies with reactivity to SIV
antigens can be present in some MCMs (at variable levels). The mechanism(s) for generating
these antibodies remain to be understood. We speculate that endogenous or environmental
antigens may induce antibodies with cross-reactivity to SIV antigens and subject to regulation
by external stimuli [35, 37]. Our results also showed that the PCS vaccine elicited mucosal anti-
bodies not only to the PCSs but also to non-PCS Gag and Env antigens. While several possibili-
ties may account for this observation [35, 37], one of them may be the cross-reactivity of the
anti-PCS antibodies to the non-PCS antigens [76]. Although there is no similarity in primary
Fig 6. Induction of antibodies to Gag/Env antigens. (A) Graphs show fold changes of mucosal IgG antibodies to
Gag/Env (non-PCS) peptides (SIVgag, SIVenv1 and SIVenv2) between the time of a prime/boost and one week after
that single prime/boost (Prime, 1st, 2nd, 3rd or 4th), or between the baseline (the start of the full vaccination procedure)
and one week after the last boost (the end of the full vaccination procedure) (Full). The Control group received empty
rVSV virus and sterile water. Data are shown as each value from individual animals with interquartile range and
median line. Total animal numbers per group examined are n = 8 (Control or PCS group) or n = 7 (Gag/Env group).
However, for technical stringency, animal samples collected on menstruation dates were excluded from analysis to rule
out any potential menses blood contamination. As a result, for some of the data points in the graph, fewer individual
values than the total animal number (n = 8 or n = 7) were available. Fold changes of antibodies to SIVgag and SIVenv1
in response to prime, the 1st boost, the 4th boost and the full vaccination procedure showed trends of increase in the
PCS vaccine group, compared to the other groups. The trends did not reach statistical significance. (B) Reactivity of
mucosal IgG antibodies to Gag and Env proteins. Western blot membranes containing purified recombinant Gag
(rGag) or Env (rEnv) protein (NIH AIDS Reagent Program) were used to probe anti-Gag/Env IgG antibodies in CVL
samples, collected at one week after the last boost from animals of the PCS vaccine (animal ID: cy0759), Gag/Env
vaccine (animal ID: cy0784) and Control (animal ID: cy0779) groups, respectively.
https://doi.org/10.1371/journal.pone.0202997.g006
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sequences between the PCS and non-PCS peptides, they may have similar conformational
structures that could contribute to cross-reactivity [76]. It is important to note that the induc-
tion of antibodies with reactivity to non-PCS peptides did not distract the PCS vaccine away
from its intended targets, the PCSs, since the PCS vaccine was shown to effectively elicit anti-
bodies to these targets. The cross-reactivity of the PCS vaccine-induced antibodies expands the
antigen spectrum to additional Gag and Env epitopes. As a result, the PCS vaccine may have
the potential to target both PCS-based viral maturation and Env-mediated viral entry. These
will need to be further investigated.
In conclusion, our study showed that the PCS vaccine and Gag/Env vaccine can induce
mucosal IgG responses to SIV immunogens, including PCS peptides and Gag and Env pro-
teins. The effect of these vaccine-induced mucosal antibodies in protecting macaques from
pathogenic SIVmac251 low dose intravaginal challenges will be determined in on-going
studies.
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Figure A. The PCS vaccine group: Mucosal IgG responses to PCSs in each individual animal. 
Cervicovaginal lavage (CVL) samples of the PCS vaccine group animals from the vaccination experiments 
illustrated in Figure 1E were analyzed for antibodies to PCS peptides using a Bio-Plex multiplexed 
antibody assay. Each panel represents one animal, with animal ID and MHC haplotypes (MHC I, MHC II) 
shown on top. Data from one animal (ID cy0758) were excluded due to sample collection on concurrent 
menstruation dates. Antibody levels (ratios of anti-PCS IgG concentration to total protein concentration, 
timed by 109) in each animal were compared between the baseline (indicated as “B” on x axis) and after 
the vaccination procedure (one week after the last boost, indicated as “V” on x axis). Each line represents 
IgG antibody levels to one PCS type, connecting data points before and after vaccination. 
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Figure B. The Gag/Env vaccine group: Mucosal IgG responses to PCSs in each individual animal. 
Antibodies to PCS peptides were analyzed and graphed as in Figure A. Data from two animals were 
excluded due to the following reasons: cy0782 was euthanized early due to health issues unrelated to 
vaccination. Sample collection of cy0788 involved concurrent menstruation dates. 
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Figure C. The Control group: Mucosal IgG responses to PCSs in each individual animal. Antibodies 
to PCS peptides were analyzed and graphed as in Figure A. 
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Figure D. PCS vaccine group: Mucosal IgG responses to Gag/Env peptides (non-PCS) in each 
individual animal. Antibodies to Gag/Env peptides were analyzed and graphed similarly to Figure A. 
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Figure E. Gag/Env vaccine group: Mucosal IgG responses to Gag/Env peptides (non-PCS) in each 
individual animal. Antibodies to Gag/Env peptides were analyzed and graphed similarly to Figure B. 
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Figure F. Control group: Mucosal IgG responses to Gag/Env peptides (non-PCS) in each individual 
animal. Antibodies to Gag/Env peptides were analyzed and graphed similarly to Figure C. 
